The results of 5-year experience in testing the glomerular filtration rate by the INVITRO laboratory in the territory of the Russian Federation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Assessment of the distribution of test results for the estimated glomerular filtration rate by stages of CKD (from 1 to 5 as renal function decreases), as well as assessment of the possibility of detecting of patients with a high stage of asymptomatic CKD at the initial screening. Materials and methods: 77,719 tests were analyzed for the period 01.12.2014 - 28.10.2020. For the analysis, data selected from the unified INVITRO database and completely (irreversibly) depersonalized were used. Results: More than half of the remaining results (63,920 tests) were abnormal (GFR <90). Over 5 years of follow-up, the number of such patients was 32,235 (50.5%), 6866 (10.8%) cases of serious deviations (CKD stage 3-5). The dynamics of GFR testing showed a gradual increase in the number of tests starting at the end of 2014 (when this test began to carried out in INVITRO) from 0 to 500 tests per month taken from corporate clients and 1000 tests per month taken from patients without referral. The prevalence of CKD stage 3-5 among adults was 2.7%. In October 2018, a significantly lower percentage of identified CKD stage 3-5 and a significantly higher percentage of normal GFR values were recorded. These results were obtained during a publicity campaign, and active educational work in the media, including central television and popular highcirculation magazines during the period of 2018

Full Text

Restricted Access

About the authors

D. V Fadin

INVITRO Company

Director for Strategic Development and Innovation Moscow, Russia

V. A Fedin

OOO «INVITRO»

General Director Moscow, Russia

B. V Zingerman

OOO TelePat

Scientific Director Moscow, Russia

O. N Kotenko

Moscow City Scientific and Practical Center for Nephrology and Kidney Transplant Pathology City Clinical Hospital № 52 of the Moscow Healthcare Department

Cand. Sci. (Med.), Chief External Expert in Nephrology of the Moscow Healthcare Department, Head Moscow, Russia

I. G Kargalskaya

OOO TelePat

Head of the Patient-Oriented Telemedicine Committee at the All-Russian Union of Patients Moscow, Russia

References

  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2 suppl 1): S1-S266.
  2. Rettig R.A., Norris K., Nissenson A.R. Chronic kidney disease in the United States: a public policy imperative. Clin J Am Soc Nephrol. 2008;3:1902-1910.
  3. Melamed M.L., Bauer C., Hostetter T.H. eGFR: is it ready for early identification of CKD? Clin J Am Soc Nephrol. 2008;3(5):1569-1572.
  4. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensinconvertingenzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
  5. Дудко М.Ю., Котенко О.Н., Шутов Е.В., Васина Н.В. Эпидемиология хронической болезни почек среди жителей города Москвы. Клиническая нефрология. 2019;3:37-41.
  6. Отчет ООО «ИНВИТРО-Объединенные коммуникации» от 18.05.2020. [Report of INVITRO-United Communications LLC dated 18.05.2020 (In Russ.)].
  7. Hill N.R. et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS ONE. 2016; 11:e0158765.
  8. Zhang L. et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012; 379:815-822.
  9. Arora P. et al. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ. 2013;185: E417-E423.
  10. White S.L., Polkinghorne K.R., Atkins R.C., Chadban S.J. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am. J. Kidney Dis. 2010;55:660-670.
  11. Levey A.S., Coresh J. Chronic kidney disease. Lancet. 2012;379:165-180.
  12. Girndt M., Trocchi P., Scheidt-Nave C., Markau S. Stang A. The prevalence of renal failure. Results from the German Health Interview and Examination Survey for Adults, 2008-2011 (DEGS1). Dtsch. Arztebl. Int. 2016;113:85-91.
  13. Bruck K. et al. CKD prevalence varies across the European general population. J. Am. Soc. Nephrol. 2016;27:2135-2147.
  14. Fraser S.D. et al. Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey for England. PLoS ONE 2015;10:e0118676.
  15. Codreanu I., Perico N., Sharma S.K., et al. Prevention programmes of progressive renal disease in developing nations. Nephrology. 2006;11:321-328.
  16. Li P.K., Weening J.J., Dirks J., et al. Participants of ISN Consensus: Workshop on Prevention of Progression of Renal Disease. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl. 2005;94:S2-S7.
  17. Levey A.S., Atkins R., Coresh J., et al: Chronic kidney disease as a global public health problem: Approaches and initiatives - A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247-259.
  18. Archibald G., Bartlett W., Brown A., et al. UK Consensus Conference on Early Chronic Kidney Disease. Nephrol Dial Transplant 22:Six4-Six5, 2007;suppl. 9.
  19. Vassalotti J.A., Stevens L.A., Levey A.S. Testing for chronic kidney disease: A position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50:169-180.
  20. Imai E., Yamagata K., Iseki K., et al. Kidney disease screening program in Japan: History, outcome, and perspectives. Clin J Am Soc Nephrol. 2007;2:1360-1366.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies